Home / Biosimilars / General / Also noted on biosimilars: 6 April 2012

Also noted on biosimilars: 6 April 2012 Posted 06/04/2012

Amgen and AstraZeneca make monoclonal antibody deal
Biotech giant Amgen and pharma major AstraZeneca announced on 2 April 2012 an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab [AMG 827]), which are expected to be used to treat inflammatory diseases.

As part of the deal AstraZeneca will make an upfront payment of US$50 million and the companies will then share both costs and profits. The collaboration will provide Amgen with additional resources to optimally progress its portfolio and Amgen will benefit from the strong respiratory, inflammation and asthma development expertise of MedImmune–AstraZeneca’s biologicals arm.

Related articles

Amgen finally jumps on biosimilars bandwagon

AstraZeneca expands its generics business with Indian agreements

Source: Amgen, AstraZeneca

Lupin on track with first biosimilar
Rumour is that India-based generics manufacturer Lupin is on track to release its first biosimilar in India in the first quarter of 2012, depending on regulatory approval.

Experts believe that Lupin’s most advanced biosimilar is a copy of Amgen's Neupogen (filgrastim). Lupin is also working on a biosimilar version of Amgen's Neulasta (pegfilgrastim), but it is believed that the filgrastim biosimilar is the most likely candidate to be released first.

Source: BioPharmInsight

Comments (0)